MLYS

SEC filing MLYS Shareholders Elect Class III Directors, Ratify EY as Auditor

10d ago

Insider trade Sale by David Malcom Rodman (Chief Medical Officer)

19d ago

Insider trade Sale by David Malcom Rodman (Chief Medical Officer)

19d ago

Insider trade Sale by David Malcom Rodman (Chief Medical Officer)

19d ago

News Mineralys outlines lorundrostat U.S. launch plans ahead of December 22, 2026 PDUFA

26d ago

Insider trade Sale by David Malcom Rodman (Chief Medical Officer)

38d ago

Insider trade Sale by David Malcom Rodman (Chief Medical Officer)

41d ago

Insider trade Sale by David Malcom Rodman (Chief Medical Officer)

47d ago

Insider trade Sale by Jon Congleton (Chief Executive Officer)

47d ago

Insider trade Sale by David Malcom Rodman (Chief Medical Officer)

49d ago

Insider trade Sale by David Malcom Rodman (Chief Medical Officer)

76d ago

Insider trade Sale by David Malcom Rodman (Chief Medical Officer)

77d ago

News Mineralys targets December 2026 lorundrostat approval as payer engagement and data drive launch strategy

81d ago

SEC filing MLYS Reports $656.6M Cash, $132M R&D, FDA Accepts Lorundrostat NDA, PDUFA Dec 22 2026

81d ago

Insider trade Sale by David Malcom Rodman (Chief Medical Officer)

83d ago

News Mineralys spikes as blood pressure drug undergoes FDA review

83d ago

Insider trade Sale by David Malcom Rodman (Chief Medical Officer)

104d ago

Insider trade Sale by David Malcom Rodman (Chief Medical Officer)

104d ago

Insider trade Sale by Jon Congleton

104d ago

Insider trade Sale by David Malcom Rodman

104d ago

Insider trade Sale by David Malcom Rodman

104d ago

Insider trade Sale by David Malcom Rodman

104d ago

News M/I Homes signals 5% community count growth in 2026 while navigating margin pressures

124d ago

News Crystalys Therapeutics Expands Leadership Team with Appointment of Justin Thacker as Chief Financial Officer to Support Advancement of Phase 3 Trials of Dotinurad

132d ago

Scanner Unusual volume (z=6.4)

160d ago